Ven-105

Ven-105 is an investigational recombinant protein being developed by Ventria Bioscience for the treatment of inflammatory bowel diseases (IBD). The drug is produced using Ventria's proprietary ExpressTec platform, which utilizes a plant-based (rice) expression system to manufacture recombinant human proteins. While the specific molecular identity and target of Ven-105 have not been publicly disclosed, the candidate is part of Ventria's therapeutic pipeline focused on infectious and inflammatory diseases. It is designed to leverage the company's expertise in producing bioactive proteins that can modulate the gastrointestinal environment, potentially offering a new approach to managing the chronic inflammation associated with Crohn's disease and ulcerative colitis.